T cells in health and disease
L Sun, Y Su, A Jiao, X Wang, B Zhang - Signal transduction and …, 2023 - nature.com
T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …
T-cell-engaging bispecific antibodies in cancer
NWCJ van de Donk, S Zweegman - The Lancet, 2023 - thelancet.com
T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …
Targeting public neoantigens for cancer immunotherapy
Several current immunotherapy approaches target private neoantigens derived from
mutations that are unique to individual patients' tumors. However, immunotherapeutic …
mutations that are unique to individual patients' tumors. However, immunotherapeutic …
Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1+ PD-1+ CD8 T cells
E Humblin, I Korpas, J Lu, D Filipescu… - Science …, 2023 - science.org
During persistent antigen stimulation, such as in chronic infections and cancer, CD8 T cells
differentiate into a hypofunctional programmed death protein 1–positive (PD-1+) exhausted …
differentiate into a hypofunctional programmed death protein 1–positive (PD-1+) exhausted …
The present and future of bispecific antibodies for cancer therapy
Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …
applications that cannot be achieved using conventional IgG-based antibodies …
Fcγ receptors and immunomodulatory antibodies in cancer
The discovery of both cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and
programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to …
programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to …
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
C Claus, C Ferrara-Koller, C Klein - MAbs, 2023 - Taylor & Francis
The clinical development of 4–1BB agonists for cancer immunotherapy has raised
substantial interest during the past decade. The first generation of 4–1BB agonistic …
substantial interest during the past decade. The first generation of 4–1BB agonistic …
The state of the art of bispecific antibodies for treating human malignancies
S Wang, K Chen, Q Lei, P Ma, AQ Yuan… - EMBO molecular …, 2021 - embopress.org
Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been
extensively explored in translational and clinical studies since they were first developed in …
extensively explored in translational and clinical studies since they were first developed in …
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models
J Wei, W Montalvo-Ortiz, L Yu, A Krasco… - Science translational …, 2022 - science.org
Although many patients with diffuse large B cell lymphoma (DLBCL) may achieve a
complete response to frontline chemoimmunotherapy, patients with relapsed/refractory …
complete response to frontline chemoimmunotherapy, patients with relapsed/refractory …